Published in Clin Trials on June 22, 2010
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | NCT00002540
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer. Am J Epidemiol (2015) 1.48
The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making (2011) 0.96
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
What do the screening trials really tell us and where do we go from here? Urol Clin North Am (2014) 0.84
Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev (2014) 0.84
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst (2014) 0.82
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol (2012) 0.81
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol (2016) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2015) 0.79
Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review. PLoS One (2016) 0.78
Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum. J Clin Oncol (2016) 0.77
PSA screening for prostate cancer: why so much controversy? Asian J Androl (2013) 0.77
Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity? Cancer Epidemiol Biomarkers Prev (2012) 0.76
Re: Determinants of participation in prostate cancer screening: A simple analytical framework to account for healthy-user bias. Cancer Sci (2015) 0.75
Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. Med Care (2013) 0.75
Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). EJIFCC (2014) 0.75
Prostate cancer: Why the prostate arm of the PLCO trial failed and what it has taught us. Nat Rev Urol (2016) 0.75
What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiol (2016) 0.75
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2005) 2.24
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76
Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet (2005) 1.67
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60
The short-term growth response to salt of the developing barley leaf. J Exp Bot (2006) 1.57
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
A population approach to precision medicine. Am J Prev Med (2012) 1.44
The Arabidopsis nitrate transporter NRT2.4 plays a double role in roots and shoots of nitrogen-starved plants. Plant Cell (2012) 1.41
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer (2009) 1.22
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc (2012) 1.18
National Children's Study: update in 2010. Mt Sinai J Med (2011) 1.17
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer (2009) 1.15
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics (2005) 1.15
Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med (2012) 1.14
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? BMC Med Res Methodol (2004) 1.11
Two-photon absorption and self-phase modulation measurements with shaped femtosecond laser pulses. Opt Lett (2005) 1.10
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer (2005) 1.08
Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis. Stat Methods Med Res (2005) 1.08
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. J Thorac Oncol (2009) 1.03
IARC monographs: 40 years of evaluating carcinogenic hazards to humans. Environ Health Perspect (2015) 1.03
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. Urol Oncol (2004) 1.03
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials (2010) 1.01
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol (2003) 0.99
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int (2010) 0.97
Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis (2007) 0.95
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol (2011) 0.93
Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol (2013) 0.92
Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer (2002) 0.91
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol (2006) 0.91
Fruits and vegetables and prostate cancer: no association among 1104 cases in a prospective study of 130544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer (2004) 0.89
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89
Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected. Stat Med (2009) 0.88
Delivery of preventive care: the national Canadian Family Physician Cancer and Chronic Disease Prevention Survey. Can Fam Physician (2012) 0.88
Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol (2004) 0.88